Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase IIα, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas

Human Pathology

Volumn 35, Issue 6, 2004, Pages 745-751

  Hafian, Hilal ^a   Venteo, Lydie ^a   Sukhanova, Alyona ^a   Nabiev, Igor ^a   Lefevre, Benoît ^a   Pluot, Michel ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

DNA topoisomerase I; DNA topoisomerase II alpha; immunohistochemistry; MD; OIN; oral intraepithelial neoplasia; oral intraepithelial neoplasia (OIN); oral squamous cell carcinoma; topo I; topoII

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE 2 ALPHA; ENZYME ANTIBODY; ISOENZYME; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CORRELATION ANALYSIS; DYSPLASIA; EPITHELIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PRECANCER; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042766238     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.02.004     Document Type: Article

References (36)

1. Pommier Y., Pourquier P., Fan Y., et al. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:1998;83-106
2. Sweart L., Redinbo M.R., Qiu X., et al. A model for the mechanism of human topoisomerase I. Science. 279:1998;1534-1542
3. Holden J.A. Human DNA topoisomerases Molecular targets anticancer drugs. Ann Clin Lab Sci. 27:1997;402-412
4. Hasiang Y.H., Hertzber G.R., Hecht S., et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase. J Biol Chem. 260:1989;14873-14878
5. Covey J.M., Jaxel C., Kohn K.W., et al. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:1989;5016-5022
6. Nitiss J.L., Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol. 50:1996;1095-1102
7. Bjornesti M., Benedetti P., Viglianti G.A., et al. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I Restoration of sensitivity of sensitivity of the cells to the antitumor drugs camptothecin. Cancer Res. 46:1989;6318-6323
8. Hann C., Evans D.L., Fertala J., et al. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I. J Biol Chem. 273:1998;8425-8433
9. Madden K.R., Champoux J.J. Overexpression of human topoisomerase in baby hamster kidney cells Hypersensitivity of clonal isolates to camptothecin. Cancer Res. 52:1992;525-535
10. Bronstein I.B., Vorobyev S., Timofeev A., et al. Elevation of topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res. 8:1996;17-25
11. Nittis J.L., Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol. 50:1996;1109-1112
12. Ryan A.J., Squires S., Strutt H.L., et al. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double stand breaks in replicating DNA. Nucl Acids Res. 19:1991;3295-3300
13. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967
14. Caserini C., Pratesi G., Tortoreto M., et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors. Clin Cancer. 3:1997;955-961
15. Bourhis J., Pignon J., Designe L. Meta-analysis of chemotherapy in head and neck cancer (MHACH-NC) Locoregional treatment vs same treatment + chemotherapy (CT). Proc Am Soc Clin Oncol. 17:1998;386a. (abstr)
16. Munor A. Meta-analysis of chemotherapy in head and neck cancer. Br J Cancer. 7:1995;83-91
17. Murphy B., Leong T., Burkey B., et al. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck An Eastern Cooperative Group trial (E3393)). Am J Clin Oncol. 24:2001;64-66
18. Robert F., Soong S., Wheeler R., et al. A phase II study of topotecan in patients with recurrent head and neck cancer Identification of an active new agent. Am J Clin Oncol. 20:1997;298-302
19. Lad T., Rosen B., Brockstein R., et al. Phase II trial of 9-aminocamptothecin (9AC/DMA) in patients with advanced squamous cell head and neck cancer. Proc Am Soc Clin Oncol. 17:1998;392a. (abstr)
20. Masin J.S., Berger S.J., Setrakian S., et al. Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laryngoscope. 105:1995;1191-1196
21. Hirata S., Katoh O., Oguri T., et al. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa. Jpn J Cancer Res. 91:2000;84-90
22. Holden J.A., Rahn M.P., Jolles C.J., et al. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma. J Clin Pathol. 50:1997;247-253
23. Lynch B.J., Guinee D.G., Holden J.A. Human DNA topoisomeraseII-alpha A new marker of cell proliferation in invasive breast cancer. Hum Pathol. 28:1997;1180-1188s
24. Gerdes J., Lemke H., Baisch H., et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1984;1710-1715
25. Duchrow M., Gerdes J., Schulter C. The proliferation-associated Ki-67 protein Definition in molecular term. Cell Prolif. 57:1997;235-242
26. Pindborg J.J., Reichart P.A., Smith C.J., et al. Histological Typing of Cancer and Precancer of the Oral Mucosa. 2nd ed. 1997;Springer-Verlag, Berlin, Germany
27. Rayhand-Diogene H., Foetin A., Morency R., et al. Markers of radioresistance in squamous cell carcinoma of the head and neck A clinicopathologic and immunohistochemical study. J Clin Oncol. 15:1997;1030-1038
28. Lavertu P., Adelstein D.J., Myles J., et al. p53 and KI-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemo radiotherapy. Laryngoscope. 111:2001;. 1892-1878
29. Woesser R.D., Mothren M.R., Miabelli C.K., et al. Proliferation and cell cycle-dependent differences in the expression of the 170 kilodalton and 180 kilodalton froms of topoisomerases II in NIH-3T3 cells. Cell Growth Differ. 2:1991;209-214
30. Nakopoulou L., Zervas A., Lazaris A.Ch., et al. Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma. J Clin Pathol. 54:2001;309-313
31. Gibbons D., Fogt F., Holden J., et al. Comparaison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions. Mod Pathol. 10:1997;409-413
32. Brustmann H., Naude S. Expression of topoisomerase II-alpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions. Gynecol Oncol. 86:2002;192-199
33. Pitot H.C., Wender D.B., O'Connell M.J., et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 15:1997;2910-2919
34. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer Results of a large European phase II sudy. J Clin Oncol. 14:1996;3056-3061
35. Mc Donald A.C., Brown D.G.R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase I inhibitors. Br J Cancer. 78:1997;745-751
36. Lynch B.J., Komaromy-Hiller G., Bronstein I.B., Holden J.A. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol. 29:1998;1240-1245